Edgewise Therapeutics prices $200 million stock offering to advance muscular and cardiac therapies

On April 2, 2025, Edgewise Therapeutics announced the pricing of an underwritten public offering of its common stock, aiming to raise approximately $200 million. Shares were priced at $20.13 each. The offering is expected to close on April 3, 2025, pending customary closing conditions.

The deal attracted participation from prominent institutional investors including Braidwell LP, Cormorant Asset Management, Driehaus Capital Management, Invus, Janus Henderson, MPM BioImpact, OrbiMed, Paradigm BioCapital, Perceptive Advisors, RA Capital, and Sofinnova Investments.

Edgewise plans to use the proceeds to support the potential U.S. commercial launch of its lead candidate sevasemten for Becker muscular dystrophy, if approved, and to advance Phase 3 trials of the same therapy for Duchenne muscular dystrophy. Additional funds will go toward Phase 3 trials of EDG-7500 for hypertrophic cardiomyopathy and other research and development efforts, as well as general corporate needs.

Leerink Partners, Piper Sandler, Guggenheim Securities, and Truist Securities served as joint book-running managers for the offering.

Edgewise specializes in developing treatments for muscular dystrophies and cardiac conditions, with two main clinical programs: sevasemten, a skeletal myosin inhibitor, and EDG-7500, a cardiac sarcomere modulator.